Thanks to a key provision in the Inflation Reduction Act, Medicare is now permitted to start negotiating for more affordable pharmaceutical drugs.

While negotiations will conclude next year and new costs will not go into effect until January 1, 2026, this is a major step in reining in the greed that has dominated the pharmaceutical industry and its obscene lobbying efforts responsible for pouring over $700 million over the past two years into trying to undermine the law.

Those who rely on medication that did not make the initial list will still benefit as early as next year from the accrued Medicare savings aiming to cut thousands per year in out-of-pocket costs for many seniors by increasing the Part-D drug benefit.

This is projected to help more than nine million people who will save $100 billion over the next decade.

This is what good government looks like.

For more information about the Inflation Reduction Act and how its impact is providing the most robust infrastructure investment in almost a hundred years, visit build.gov.